Cabaletta Bio (CABA, $12.18) was a top loser over the last three months, falling -4 to $12.18 per share. A.I.dvisor analyzed 913 stocks in the Biotechnology Industry for the 3-month period ending April 25, 2024, and found that of them (4) exhibited an Uptrend while of them (5) demonstrated a Downtrend.
a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases